HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Saw Palmetto "Moderate" Quality Evidence Shows BPH Symptom Relief - USP

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Pharmacopeia's final monograph on saw palmetto lists 10 published studies on the ingredient that met the USP quality standard of Level II or higher, under the organization's new criteria for evidence submission for botanicals.

You may also be interested in...

USP Ephedra Review Scheduled For July; RAND Report Slated For Early Fall

The U.S. Pharmacopeia will discuss standard-setting issues related to the supplement ingredient ephedra during an internal meeting July 17

USP Docosahexaenoic Acid Monograph Previewed, Others Revised

The U.S. Pharmacopeia has released National Formulary preview monographs for docosahexaenoic acid, DHA oil and DHA capsules; the monographs appear in the November-December Pharmacopeial Forum.

CR Saw Palmetto Review Produces Mixed Results; More Tests Upcoming

Only eight of 13 saw palmetto supplements tested by Consumer Reports contain an adequate amount of the extract, the magazine reports in its September issue.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts